Skip to main content
OpenTrials
Completed

NCT Number: NCT00634361

Ethyl-EPA Treatment of Prodromal Patients

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Prodrome

Age range

14 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • meets criteria for schizophrenia prodrome

Exclusion criteria

  • any lifetime antipsychotic treatment

Treatment and study plan

ethyl-eicosapentaenoic acid

Drug

2 mg per day

Other names: ethyl-EPA, an omega-3 fatty acid

Primary outcomes

  1. conversion to psychosis

    Time frame: one year

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Important dates

Study start
2001
Primary completion
2005
Study completion
2005
First posted
Mar 13, 2008
Registry last updated
May 22, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.